Navigation Links
NeurogesX Appoints New Board Director and Audit Committee Chairman
Date:8/25/2009

ng novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NeurogesX Reports Second Quarter 2009 Results
2. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
3. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
4. NeurogesX Added to Russell 3000 Index
5. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
6. NeurogesX to Present at Needham Life Sciences Conference
7. NeurogesX Receives European Commission Approval for Qutenza(TM)
8. NeurogesX Reports First Quarter 2009 Results
9. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
10. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
11. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/29/2015)... -- According to a new market research report, ... (2015-2020), , published by Mordor Intelligence, the Global market is ... of 2020, with North America being ... the global market size. The Global market for Stem Cells ... the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) , ...
(Date:7/29/2015)...  AsureQuality and Ubiquitome have agreed to collaborate ... food and primary production sectors. The collaboration will ... the Freedom4. AsureQuality provides quality assurance ... shelf for producers, processors and Competent Authorities around ... control and pest management and surveillance programmes. ...
(Date:7/29/2015)... 29, 2015  Therapath Neuropathology ( www.Therapath.com ), ... with VA and Military Medical centers both domestically ... (ENFD) and Sweat Gland Nerve Fiber Density (SGNFD) ... https://therapath.com/skin ). Demonstration of a ... on punch skin biopsy is a highly sensitive ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Neuropathology services for VA and Military health systems 2
... NEWTON, Mass., Aug. 11 Microfluidics International Corporation (OTC Bulletin ... June 30, 2009. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090811/NE59652LOGO ... , , Achieved positive earnings before ... Delivered strong bookings of $6.6 million with a backlog ...
... , BEIJING, Aug. 11 /PRNewswire-Asia/ -- ... provider of vaccines in China, today announced,that it will host ... a.m.,ET to review the Company,s second quarter financial results for ... recent corporate developments. , To access ...
... , , WALTHAM, Mass., Aug. ... advisory firms for pharmaceutical and healthcare issues, finds that the entry ... drug market to more than quadruple from approximately $420 million in ... The new Pharmacor report entitled Systemic Lupus Erythematosus ...
Cached Biology Technology:Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 2Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 3Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 4Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 5Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 6Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 7Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 8Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 9Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results 2Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018 2
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... months of age and after 6 months may have a ... researchers have found. The researchers, from the Colorado School ... Davis Center for Diabetes, also found that the risk goes ... solid foods, particularly those containing wheat or barley, are introduced ...
... on Spinal Cord Injury Research awarded three grants to scientists ... studies of assisted walking with Ekso, the impact of aging ... effects of electrical stimulation on bone loss. "Thanks to ... find new treatments that improve the function and quality of ...
... D.C. -- Christopher Field, the founding director of Carnegie,s ... of Germany,s most prestigious prizes, the Max Planck Research ... our knowledge of how life on Earth responds to ... the biosphere and the atmosphere their work also helps ...
Cached Biology News:Infants' food linked to higher, lower Type 1 diabetes risk 2Kessler Foundation awarded more than $1.2 million in grants by the NJ Commission on Sci Research 2Kessler Foundation awarded more than $1.2 million in grants by the NJ Commission on Sci Research 3Carnegie's Chris Field receives Max Planck Research Prize 2
... are hydrophobic cover slips for in ... genomic arrays on glass slides., ... Hybri-slips do not adsorb probes. , ... to use. , Avoid RNA degradation-Hybri-slips ...
...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... ] to PRKAR2 cAMP is a ... cellular functions. cAMP exerts its effects by ... transduces the signal through phosphorylation of different ... is a tetramer composed of two regulatory ...
Biology Products: